硼替佐米两种给药方案的疗效比较:暴露-反应分析
本研究利用VISTA试验和ALCYONE试验对照组数据,通过暴露-反应分析比较硼替佐米原研给药方案与较低频率给药方案(九个6周治疗周期)的疗效。结果显示,对所有终点和方案,临床缓解概率与累积硼替佐米剂量相关;较低频率给药方案疗效相当且累积剂量更高,可能部分源于毒性降低和剂量调整/中断减少。
要点
- 临床缓解概率与累积硼替佐米剂量相关,适用于所有终点和方案。
核心结论
- 较低频率硼替佐米给药方案疗效与原研方案相当,且累积剂量更高。
研究设计与样本
- 基于VISTA临床试验和ALCYONE临床试验对照组数据的暴露-反应分析,比较原研与较低频率给药方案(九个6周治疗周期)的疗效。
主要发现
- 对所有终点和方案,临床缓解概率与累积硼替佐米剂量相关。
临床怎么用
- 较低频率硼替佐米给药可在保持疗效的同时提高累积剂量,可能因毒性降低和剂量调整/中断减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bortezomib is a first-in-class proteasome inhibitor, approved for the treatment of multiple myeloma. The originally approved dosing schedule of bortezomib results in significant toxicities that require dose interruptions and discontinuations. Consequentially, less frequent dosing has been explored to optimise bortezomib's benefit-risk profile. Here, we performed exposure-response analysis to compare the efficacy of the original bortezomib dosing regimen with less frequent dosing of bortezomib over nine 6-week treatment cycles using data from the VISTA clinical trial and the control arm of the ALCYONE clinical trial. The relationship between cumulative bortezomib dose and clinical response was evaluated with a univariate logit model. The median cumulative bortezomib dose was higher in ALCYONE versus VISTA (42·2 vs. 38·5 mg/m2 ) and ALCYONE patients stayed on treatment longer (mean: 7·2 vs. 5·8 cycles). For all endpoints and regimens, probability of clinical response correlated with cumulative bortezomib dose. Similar to results observed for VISTA, overall survival was longer in ALCYONE patients with ≥ 39·0 versus < 39·0 mg/m2 cumulative dose (hazard ratio, 0·119; P < 0·0001). Less frequent bortezomib dosing results in comparable efficacy, and a higher cumulative dose than the originally approved bortezomib dosing schedule, which may be in part be due to reduced toxicity and fewer dose reductions/interruptions.
引用
- Parasrampuria DA, He J, Zhang L, et al. Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis. Br J Haematol. 2020. PMID: 32068255. doi:10.1111/bjh.16446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。